title: Expanded use of surfactant therapy in newborns.
abstract: Although there is no doubt that administration of exogenous surfactant to very preterm babies who have respiratory distress syndrome is safe and efficacious, surfactant inactivation or deficiency plays a role in the pathophysiology of other pulmonary disorders affecting newborn infants. Preliminary data suggest that there may be a role for surfactant administration to babies who have meconium aspiration syndrome, pneumonia, and possibly bronchopulmonary dysplasia. Further investigation is necessary but seems warranted.
authors: Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada. thierrylacaze@cha.ab.ca
authors: Thierry
authors: T
authors: Lacaze-Masmonteil
mesh_terms: D000818:Animals; D006801:Humans; D007231:Infant, Newborn; D008171:Lung Diseases / Q000188:drug therapy*; D011650:Pulmonary Alveoli / Q000187:drug effects* / Q000473:pathology; D011663:Pulmonary Surfactants / Q000494:pharmacology / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy
chemical_list: D011663:Pulmonary Surfactants